Scientific Leader Job at Caribou Biosciences, Inc in Berkeley, California endpts.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from endpts.com Daily Mail and Mail on Sunday newspapers.
Posted on 350
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the appointment of Jason O’Byrne as Chief Financial Officer (CFO). An accomplished executive with more than 20 years of experience within high-growth biotechnology environments, Mr. O’Byrne most recently served as Senior Vice President of Finance at Audentes Therapeutics.
“Jason’s deep experience in establishing growth-focused financial and operational infrastructures and executing successful financing strategies within the life sciences make him an ideal addition to Caribou’s executive leadership team,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “We are delighted to welcome Jason to Caribou and excited to leverage his expertise in the genetic medicines space as we continue to advance our promising allogeneic CAR-T and CAR-NK cell therapies in on
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
ABBVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor -T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection …
– ABBVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection of allogeneic CAR-T c